RB
Therapeutic Areas
Acumen Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sabirnetug (ACU193) - Intravenous (IV) | Early Alzheimer's Disease | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Early Alzheimer's Disease | Phase 1 |
| Enhanced Brain Delivery (EBD™) Platform | Neurodegenerative Diseases | Preclinical |
Leadership Team at Acumen Pharmaceuticals
DO
Daniel O’Connell
Chief Executive Officer
JD
Jim Doherty, PhD
President & Chief Development Officer
ES
Eric Siemers, MD
Chief Medical Officer
MZ
Matthew Zuga
Chief Financial Officer & Chief Business Officer
AS
Amy Schacterle, PhD
Chief Regulatory Officer & Head of Quality
DM
Derek Meisner
Chief Legal Officer, Corporate Secretary
JB
Julie Bockenstette
Chief People Officer
PS
Paul Shughrue, PhD
Vice President, Program Leader and Head of Research